[Raw data] [50 most cited papers] [50 most relevant papers] [cites used to compute IF] [Recent citations ][Frequent citing series ] [more data in EconPapers] [trace new citations] [Missing citations? Add them now] [Incorrect content? Let us know]
IF | AIF | CIF | IF5 | DOC | CDO | CIT | NCI | CCU | D2Y | C2Y | D5Y | C5Y | SC | %SC | CiY | II | AII | |
1990 | 0 | 0.14 | 0 | 0 | 3 | 3 | 0 | 0 | 3 | 4 | 0 | 0 | 0.07 | |||||
1991 | 0 | 0.11 | 0 | 0 | 2 | 5 | 0 | 0 | 4 | 6 | 0 | 0 | 0.06 | |||||
1992 | 0 | 0.1 | 0 | 0 | 1 | 6 | 0 | 0 | 5 | 8 | 0 | 0 | 0.07 | |||||
1993 | 0 | 0.13 | 0 | 0 | 1 | 7 | 0 | 0 | 3 | 9 | 0 | 0 | 0.07 | |||||
1994 | 0 | 0.13 | 0 | 0 | 2 | 9 | 0 | 0 | 2 | 8 | 0 | 0 | 0.06 | |||||
1995 | 0 | 0.18 | 0 | 0 | 1 | 10 | 6 | 0 | 3 | 9 | 0 | 0 | 0.09 | |||||
1996 | 0 | 0.21 | 0.1 | 0 | 0 | 10 | 0 | 1 | 1 | 3 | 7 | 0 | 0 | 0.12 | ||||
1997 | 0 | 0.23 | 0 | 0 | 3 | 13 | 1 | 1 | 1 | 5 | 0 | 0 | 0.13 | |||||
1998 | 0.33 | 0.24 | 0.06 | 0.14 | 3 | 16 | 0 | 1 | 2 | 3 | 1 | 7 | 1 | 0 | 0 | 0.15 | ||
1999 | 0 | 0.32 | 0 | 0 | 0 | 16 | 0 | 2 | 6 | 9 | 0 | 0 | 0.21 | |||||
2000 | 0.33 | 0.44 | 0.13 | 0.29 | 0 | 16 | 0 | 2 | 4 | 3 | 1 | 7 | 2 | 0 | 0 | 0.2 | ||
2001 | 0 | 0.4 | 0.06 | 0 | 0 | 16 | 0 | 1 | 5 | 0 | 6 | 0 | 0 | 0.22 | ||||
2002 | 0 | 0.42 | 0 | 0 | 0 | 16 | 0 | 5 | 0 | 6 | 0 | 0 | 0.23 | |||||
2003 | 0 | 0.42 | 0 | 0 | 1 | 17 | 0 | 5 | 0 | 3 | 0 | 0 | 0.24 | |||||
2004 | 1 | 0.47 | 0.06 | 1 | 1 | 18 | 0 | 1 | 6 | 1 | 1 | 1 | 1 | 0 | 0 | 0.27 | ||
2005 | 0 | 0.49 | 0.11 | 0 | 0 | 18 | 0 | 2 | 8 | 2 | 2 | 0 | 0 | 0.29 | ||||
2006 | 0 | 0.47 | 0.05 | 0 | 2 | 20 | 0 | 1 | 9 | 1 | 2 | 0 | 0 | 0.27 | ||||
2007 | 0 | 0.39 | 0.05 | 0 | 1 | 21 | 0 | 1 | 10 | 2 | 4 | 0 | 0 | 0.22 | ||||
2008 | 0 | 0.46 | 0.04 | 0.2 | 5 | 26 | 13 | 1 | 11 | 3 | 5 | 1 | 0 | 0 | 0.23 | |||
2009 | 0.17 | 0.43 | 0.06 | 0.11 | 6 | 32 | 22 | 2 | 13 | 6 | 1 | 9 | 1 | 1 | 50 | 1 | 0.17 | 0.22 |
2010 | 0.55 | 0.37 | 0.22 | 0.43 | 0 | 32 | 0 | 7 | 20 | 11 | 6 | 14 | 6 | 0 | 0 | 0.19 | ||
2011 | 0.17 | 0.46 | 0.03 | 0.07 | 0 | 32 | 0 | 1 | 21 | 6 | 1 | 14 | 1 | 0 | 0 | 0.25 | ||
2012 | 0 | 0.5 | 0.06 | 0.17 | 1 | 33 | 0 | 2 | 23 | 0 | 12 | 2 | 0 | 0 | 0.25 | |||
2013 | 0 | 0.5 | 0.24 | 0.58 | 0 | 33 | 0 | 8 | 31 | 1 | 12 | 7 | 0 | 0 | 0.24 | |||
2014 | 0 | 0.53 | 0.24 | 0.43 | 1 | 34 | 0 | 8 | 39 | 1 | 7 | 3 | 1 | 12.5 | 0 | 0.27 | ||
2015 | 0 | 0.53 | 0.06 | 0 | 1 | 35 | 0 | 2 | 41 | 1 | 2 | 0 | 0 | 0.27 | ||||
2016 | 0 | 0.54 | 0.05 | 0 | 2 | 37 | 0 | 2 | 43 | 2 | 3 | 0 | 0 | 0.27 | ||||
2017 | 0 | 0.54 | 0.11 | 0 | 7 | 44 | 6 | 5 | 48 | 3 | 5 | 3 | 60 | 4 | 0.57 | 0.27 | ||
2018 | 0 | 0.53 | 0.04 | 0 | 3 | 47 | 3 | 2 | 50 | 9 | 11 | 0 | 0 | 0.26 | ||||
2019 | 0 | 0.55 | 0 | 0 | 4 | 51 | 2 | 50 | 10 | 14 | 0 | 0 | 0.32 | |||||
2020 | 0.29 | 0.63 | 0.06 | 0.12 | 2 | 53 | 0 | 3 | 53 | 7 | 2 | 17 | 2 | 0 | 0 | 0.58 |
IF: | Impact Factor: C2Y / D2Y |
AIF: | Average Impact Factor for series in RePEc in year y |
CIF: | Cumulative impact factor |
IF5: | Impact Factor: C5Y / D5Y |
DOC: | Number of documents published in year y |
CDO: | Cumulative number of documents published until year y |
CIT: | Number of citations to papers published in year y |
NCI: | Number of citations in year y |
CCU: | Cumulative number of citations to papers published until year y |
D2Y: | Number of articles published in y-1 plus y-2 |
C2Y: | Cites in y to articles published in y-1 plus y-2 |
D5Y: | Number of articles published in y-1 until y-5 |
C5Y: | Cites in y to articles published in y-1 until y-5 |
SC: | selft citations in y to articles published in y-1 plus y-2 |
%SC: | Percentage of selft citations in y to articles published in y-1 plus y-2 |
CiY: | Cites in year y to documents published in year y |
II: | Immediacy Index: CiY / Documents. |
AII: | Average Immediacy Index for series in RePEc in year y |
# | Year | Title | Cited |
---|---|---|---|
1 | 2009 | Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?. (2009). Johannesson, Magnus ; Zethraeus, N ; Kobelt, G ; Jonsson, L. In: Briefings. RePEc:ohe:briefg:000228. Full description at Econpapers || Download paper | 12 |
2 | 2009 | Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries. (2009). Garau, Martina ; Mestre-Ferrandiz, J. In: Briefings. RePEc:ohe:briefg:000227. Full description at Econpapers || Download paper | 7 |
3 | 1995 | Handling Uncertainty in the Results of Economic Evaluation. (1995). Briggs, A. In: Briefings. RePEc:ohe:briefg:000410. Full description at Econpapers || Download paper | 7 |
4 | 2008 | The Market for Biosimilars: Evolution and Policy Options. (2008). Towse, Adrian ; Mestre-Ferrandiz, J ; Chauhan, D. In: Briefings. RePEc:ohe:briefg:000238. Full description at Econpapers || Download paper | 6 |
5 | 2008 | New Guidelines for Economic Evaluation in Germany and the United Kingdom: Are We Any Closer to Developing International Standards?. (2008). Rutten, F ; Drummond, M F. In: Briefings. RePEc:ohe:briefg:000237. Full description at Econpapers || Download paper | 5 |
6 | 2009 | American Exceptionalism and American Health Care: Implications for the US Debate on Cost-Effectiveness Analysis. (2009). Neumann, P J. In: Briefings. RePEc:ohe:briefg:000232. Full description at Econpapers || Download paper | 3 |
7 | 2017 | Additional Elements of Value for Health Technology Assessment Decisions. (2017). Towse, Adrian ; Karlsberg, Sarah ; Karlsberg Schaffer, Sarah ; Fischer, A ; Masterson, R ; Mestre-Ferrandiz, J ; Henshall, C ; West, P. In: Briefings. RePEc:ohe:briefg:001851. Full description at Econpapers || Download paper | 3 |
8 | 2017 | Incentives for New Drugs to Tackle Anti-Microbial Resistance. (2017). Towse, Adrian ; Mestre-Ferrandiz, J ; Ferraro, J. In: Briefings. RePEc:ohe:briefg:001842. Full description at Econpapers || Download paper | 2 |
9 | Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward. (2018). Neri, Margherita ; Garau, Martina ; Towse, A. In: Briefings. RePEc:ohe:briefg:002084. Full description at Econpapers || Download paper | 2 | |
10 | 1997 | Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry. (1997). Towse, Adrian ; Cave, M. In: Briefings. RePEc:ohe:briefg:000427. Full description at Econpapers || Download paper | 2 |
11 | 2008 | Challenges and Opportunities for Improving Benefit-Risk Assessment of Pharmaceuticals from an Economic Perspective. (2008). Garrison, L ; Cross, J T. In: Briefings. RePEc:ohe:briefg:000239. Full description at Econpapers || Download paper | 2 |
12 | 2019 | 2018 OHE Annual Report to the Charity Commission. (2019). Of, Office. In: Briefings. RePEc:ohe:briefg:002218. Full description at Econpapers || Download paper | 2 |
13 | 2019 | How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy. (2019). Sampson, Christopher ; Garau, M. In: Briefings. RePEc:ohe:briefg:002146. Full description at Econpapers || Download paper | 1 |
14 | 1979 | Immunisation for Everyone ââ¬â The Polio Experience. (1979). Of, Office . In: Briefings. RePEc:ohe:briefg:000300. Full description at Econpapers || Download paper | 1 |
15 | 1998 | Trends in Economic Evaluation. (1998). Pritchard, C. In: Briefings. RePEc:ohe:briefg:000444. Full description at Econpapers || Download paper | 1 |
16 | 2008 | Health Care Services and the Single European Market. (2008). Mountford, L ; Dawson, D. In: Briefings. RePEc:ohe:briefg:000240. Full description at Econpapers || Download paper | 1 |
17 | 2017 | Transferability of HTA. (2017). Towse, Adrian ; Hampson, Grace ; Henshall, C ; Barnsley, P. In: Briefings. RePEc:ohe:briefg:001837. Full description at Econpapers || Download paper | 1 |
18 | 2009 | Deliberative Processes in Decisions about Health Care Technologies. (2009). Culyer, Anthony. In: Briefings. RePEc:ohe:briefg:000231. Full description at Econpapers || Download paper | 1 |
19 | 2018 | OHE Annual Report to the Charity Commission for the Year 2017. (2018). Of, The Office. In: Briefings. RePEc:ohe:briefg:002079. Full description at Econpapers || Download paper | 1 |
20 | 2017 | Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies. (2017). Towse, Adrian ; Hampson, Grace ; Henshall, C. In: Briefings. RePEc:ohe:briefg:001835. Full description at Econpapers || Download paper | 1 |
21 | 2020 | 2019 OHE Annual Report to the Charity Commission. (2020). Of, Office. In: Briefings. RePEc:ohe:briefg:002315. Full description at Econpapers || Download paper | 1 |
22 | 2009 | How Fair? Competition between Independent and NHS Providers to Supply Non-Emergency Hospital Care to NHS Patients in England. (2009). Sussex, J. In: Briefings. RePEc:ohe:briefg:000230. Full description at Econpapers || Download paper | 1 |
23 | 2018 | Private Provision of Publicly Funded Health Care: The Economics of Ownership. (2018). Chalkley, Martin ; Sussex, J. In: Briefings. RePEc:ohe:briefg:002055. Full description at Econpapers || Download paper | 1 |
24 | 2004 | Developments in Economic Evaluation in Health Care: A Review of HEED. (2004). Pritchard, C. In: Briefings. RePEc:ohe:briefg:000492. Full description at Econpapers || Download paper | 1 |
25 | 1980 | Effects of Prescription Charges. (1980). Of, Office . In: Briefings. RePEc:ohe:briefg:000310. Full description at Econpapers || Download paper | 1 |
26 | 2003 | Reducing Harm to Patients in the National Health Service. Will the Governments Compensation Proposals Help?. (2003). Towse, Adrian ; Gray, Alastair ; Salinas, R ; Rickman, N ; Fenn, P. In: Briefings. RePEc:ohe:briefg:000484. Full description at Econpapers || Download paper | 1 |
# | Year | Title | Cited |
---|---|---|---|
1 | 2019 | 2018 OHE Annual Report to the Charity Commission. (2019). Of, Office. In: Briefings. RePEc:ohe:briefg:002218. Full description at Econpapers || Download paper | 2 |
Year | Title | |
---|---|---|
2020 | Taking control: Active investment choice in Singaporeâs national defined contribution scheme. (2020). Fong, Joelle H. In: The Journal of the Economics of Ageing. RePEc:eee:joecag:v:17:y:2020:i:c:s2212828x20300141. Full description at Econpapers || Download paper | |
2020 | A semi-âsmart predict then optimizeâ (semi-SPO) method for efficient ship inspection. (2020). Fagerholt, Kjetil ; Wang, Shuaian ; Yan, Ran. In: Transportation Research Part B: Methodological. RePEc:eee:transb:v:142:y:2020:i:c:p:100-125. Full description at Econpapers || Download paper |
Year | Citing document |
---|
Year | Citing document |
---|
Year | Citing document | |
---|---|---|
2017 | Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. (2017). Towse, Adrian ; Rex, John H ; Hirsch, Mark ; Hoyle, Christopher K ; Mestre-Ferrandiz, Jorge ; Goodall, Jonathan. In: Health Policy. RePEc:eee:hepoli:v:121:y:2017:i:10:p:1025-1030. Full description at Econpapers || Download paper | |
2017 | Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies. (2017). Towse, Adrian ; Hampson, Grace ; Henshall, C. In: Briefings. RePEc:ohe:briefg:001835. Full description at Econpapers || Download paper | |
2017 | Incentives for New Drugs to Tackle Anti-Microbial Resistance. (2017). Towse, Adrian ; Mestre-Ferrandiz, J ; Ferraro, J. In: Briefings. RePEc:ohe:briefg:001842. Full description at Econpapers || Download paper | |
2017 | Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?. (2017). Towse, Adrian ; Neri, Margherita. In: Briefings. RePEc:ohe:briefg:001922. Full description at Econpapers || Download paper |